AAIPharma, Inc. and Mallinckrodt Pharmaceuticals Outsourcing have established a pharmaceutical outsourcing alliance in order to deliver worldwide complementary services from drug development to high-volume commercial manufacturing. The two companies will work together to provide a one-stop drug development solution for the pharma and biopharma industries.

AAIPharma has expertise in analytical development, formulation development, bioanalysis and clinical trials. Mallinckrodt has capabilities in technical transfer for manufacturing scale-up and full-scale commercial production. Together, the two companies plan to create value for customers by utilizing collective scientific and development skills.

“Our extensive capabilities in manufacturing management coupled with AAIPharma’s long-standing strength will bring exceptional service and value to a broad spectrum of pharmaceutical companies,” said Vince Kaiman, vice president and general manager of Mallinckrodt Pharmaceuticals, a division of Tyco Healthcare.

“We are delighted to be collaborating with Mallinckrodt,” stated Vito Mangiardi, AAIPharma president of North American Operations. “This alliance significantly strengthens our ability to meet the commercial manufacturing needs of our customers worldwide. Combining AAIPharma and Mallinckrodt’s expertise will create competitive advantages for both companies and expand respective business opportunities.”